Merck has acquired CN201, a bispecific antibody, from Curon Biopharmaceutical. This acquisition strengthens Merck’s pipeline for treating B-cell malignancies and autoimmune diseases.
CN201 targets and eliminates B cells, offering potential applications in various B-cell-related conditions. Preliminary clinical trials indicate that CN201 is well-tolerated and effectively reduces B-cell populations in patients with relapsed or refractory B-cell malignancies.
Current clinical studies evaluate CN201’s efficacy in treating non-Hodgkin’s lymphoma and B-cell acute lymphocytic leukemia patients.
Under the acquisition agreement, Merck has acquired global rights to CN201. The transaction is recorded as an asset acquisition, resulting in a $750 million pre-tax charge (approximately $0.28 per share), impacting third-quarter non-GAAP results. Merck’s financial outlook for the year will be updated with the release of third-quarter 2024 results on October 31.
CN201 represents a significant addition to Merck’s research and development portfolio. Its potential to effectively eliminate B cells holds promise for treating various B-cell-associated diseases in the future.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.